Adaptive Biotechnologies Hits Day High with 9.75% Surge in Stock Price

Adaptive Biotechnologies Corp. has experienced a significant uptick in its stock performance, gaining 9.75% on May 28, 2026. The stock reached an intraday high of USD 15.21, reflecting a strong day of trading for the small-cap company in the Pharmaceuticals & Biotechnology sector. Over the past year, Adaptive Biotechnologies has outperformed the S&P 500, generating a return of 66.01% compared to the index's 28.45%. The company has shown consistent growth, with a remarkable 91.28% increase in operating profit reported in its latest results. Additionally, net sales for the first half of the year reached USD 142.56 million, marking a 42.69% growth. Despite the positive trends, the stock is considered risky relative to its historical valuations, with a notable debt-to-equity ratio of -0.40 and a return on equity of -27.18%. However, the company boasts high institutional holdings at 100%, indicating strong backing from investors with substantial resources to analyze its fundamentals. Overall, Adaptive Biotechnologies continues to demonstrate robust performance metrics amidst a dynamic market landscape.